AI-Integrated Hydrophobic Auristatin F Compounds for Enhanced Cancer Treatment
Legal Citation
Summary of the Inventive Concept
The invention integrates hydrophobic Auristatin F compounds with cutting-edge technologies such as AI, IoT, blockchain, and novel materials to create a more effective and targeted cancer treatment system.
Background and Problem Solved
The original patent disclosed hydrophobic Auristatin F compounds with activity against MDR+ cancer cells, but lacked the ability to selectively target cancer cells and monitor treatment outcomes in real-time. The new inventive concept addresses these limitations by incorporating AI-powered diagnostics, IoT-enabled wearable devices, blockchain-based tracking, and novel material-based linkers to enhance treatment efficacy and patient safety.
Detailed Description of the Inventive Concept
The new system comprises a hydrophobic Auristatin F compound conjugate integrated with an AI-powered diagnostic module that selectively targets MDR+ cancer cells with higher copy number of the targeted antigen. The conjugate is administered in combination with an IoT-enabled wearable device that monitors and adjusts the dosage based on real-time biomarker data. Additionally, the system includes a blockchain-based tracking system to ensure the authenticity and provenance of the conjugate throughout the supply chain. The kit for preparing the conjugate includes a novel material-based linker that enhances the stability and efficacy of the conjugate.
Novelty and Inventive Step
The new claims introduce the concept of integrating hydrophobic Auristatin F compounds with AI, IoT, blockchain, and novel materials, which is not obvious from the original patent. The inventive step lies in the synergistic combination of these technologies to create a more effective and targeted cancer treatment system.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include integrating the hydrophobic Auristatin F compounds with other AI-powered diagnostic tools, such as machine learning-based algorithms for predicting treatment outcomes. Variations could include using different types of IoT-enabled devices or blockchain-based tracking systems to monitor and adjust treatment regimens.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the cancer treatment market, particularly in the areas of targeted therapy and personalized medicine. The integration of AI, IoT, blockchain, and novel materials could lead to more effective and efficient treatment regimens, improving patient outcomes and reducing healthcare costs.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, specifically antibody-drug conjugates (ADCs) targeting cancer treatments, with expertise in drug design, molecular conjugation techniques, and targeted therapeutic strategies
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in pharmaceutical chemistry or bioengineering, experienced in designing targeted drug delivery systems, familiar with conjugation chemistry, cancer cell targeting mechanisms, and emerging technologies in personalized medicine
Obviousness Rationale
A PHOSITA would recognize that integrating digital technologies and advanced monitoring systems with existing drug conjugate designs represents a predictable extension of current pharmaceutical innovation. The core Auristatin F compound remains fundamentally unchanged, with the proposed variations representing incremental improvements in drug delivery and monitoring. The combination of AI, IoT, and blockchain technologies with established drug conjugate platforms would be considered a logical progression in personalized medicine approaches.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,565 |
|---|---|
| Title | Hydrophobic Auristatin F compounds and conjugates thereof |
| Assignee(s) | Seagen Inc. |